Elekta

MEDTECHS DEFLATE FURTHER

13/03/25 -"It has been some time since AlphaValue last bashed MedTechs, its recurring bête noire when it comes to lofty valuations. In fairness the sector has taken care of itself of late. Five years after ..."

PDF page sample
Pages
60
Language
English
Published on
13/03/25
Download
You may also be interested by these reports :
23/06/26
There’s an interesting paradox at the heart of Sartorius Stedim Biotech’s (SSB; ADD; France) investment case. Since our last push in February 2025, ...
03/06/26
Despite a reduction in our target price, as discussed in the EPS section, our positive recommendation on Qiagen remains unchanged. This optimism is ...
29/05/26
Elekta’s Q4 results revealed an adjusted EBIT exceeding expectations, although sales fell short. The company offered qualitative guidance for ...
26/05/26
Piling up assets is no strategy

EXECUTIVE SUMMARY

Updates Pension Risks
Target & Opinion Governance & Management
Business & Trends Graphics : Momentum
Money Making Graphics : MACD & Volumes
Debt Graphics : Sensitivities
Valuation Sector: Performance
DCF Sector: Key data
NAV/SOTP Sector: Ratios & Valorisation
Worth knowing Sector: Peers
Financials Sector: Analysis

CONFLICTS OF INTEREST

AlphaValue does not have nor seek any business with companies covered in AlphaValue Research paid by subscription. As a result, investors can be confident that there is no conflict of interest that could affect the objectivity of AlphaValue Research.

Corporate broking NO
Trading in corporate shares NO
Analyst ownership NO
Advising of corporate (strategy, marketing, debt, etc) NO
Research paid for by corporate NO
Provision of corporate access paid for by corporate NO
Link between and a banking entity NO
Brokerage activity at AlphaValue NO